^
over3years
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. (PubMed, Clin Cancer Res)
These findings demonstrate that MSLN is a viable target for CAR T therapy in AML and that inhibiting MSLN shedding is a promising approach to improve CAR T efficacy.
Journal • CAR T-Cell Therapy
|
MSLN (Mesothelin) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • ADAM17 (ADAM Metallopeptidase Domain 17)
|
MSLN positive
|
SS1(dsFv)-PE38
4years
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. (PubMed, Cancer)
The MTD for single-agent LMB-100 was found to be 140 µg/kg given on a schedule of every other day for 3 doses every 3 weeks. Although less immunogenic than the first-generation antimesothelin immunotoxin SS1P, the majority of patients developed antidrug antibodies after 2 cycles, indicating that LMB-100 has limited antitumor efficacy as a single agent. Phase 2 studies of LMB-100 plus pembrolizumab currently are ongoing for patients with mesothelioma and lung cancer.
Clinical • P1 data • Journal • PD(L)-1 Biomarker
|
MSLN (Mesothelin)
|
Keytruda (pembrolizumab) • LMB-100 • SS1(dsFv)-PE38
over4years
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. (PubMed, Biomolecules)
This has led to multiple clinical trials, testing the safety and efficacy of the clinical leads SS1P and LMB-100. This review summarizes existing pre-clinical and clinical data on MSLN-targeted iTox's. In addition, we address the potential future directions of research to enhance the activity of these anti-tumor agents.
Review • Journal
|
MSLN (Mesothelin)
|
LMB-100 • SS1(dsFv)-PE38